Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Liqun, Zou"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Explore whether the axillary outcomes differ among HER2 positive subgroups receiving standard dual-targeted therapy, aiming to identify subgroups exhibiting enhanced sensitivity to NAT among HER2-positive/node-positive breast cancer patients
Externí odkaz:
https://doaj.org/article/e4dc34516aaa401b960e4ff963b09460
Publikováno v:
Therapeutic Advances in Hematology, Vol 15 (2024)
Background: Approximately 20%–30% of diffuse large B-cell lymphoma (DLBCL) cases are classified as double-expressor lymphoma (DEL), characterized by the co-expression of the MYC and BCL2 proteins. However, the most effective therapeutic strategy fo
Externí odkaz:
https://doaj.org/article/41bda51914194b87a3fd5bc290375756
Autor:
Ningjing Lin, Xiuhua Sun, Hui Zhou, Liqun Zou, Keshu Zhou, Lihong Liu, Haiyan Yang, Kai Hu, Qingqing Cai, Yao Liu, Jie Jin, Liling Zhang, Wenyu Li, Ye Guo, Wei Yang, Feng Luo, Zhenguang Wang, Rong Zhu, Lei Yang, Dan Song, Yuqin Song, Jun Zhu
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Loncastuximab tesirine (Lonca), an antibody conjugate targeting CD19, has demonstrated significant clinical benefit in R/R DLBCL in a global phase
Externí odkaz:
https://doaj.org/article/f8f59c1272c6425db6c5b7bf6bcbf17a
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
This case report describes a 16-year-old patient with refractory Hodgkin’s lymphoma who developed bilateral anterior and intermediate uveitis as an adverse reaction to Brentuximab vedotin (BV). This is a rare case of an ocular adverse reaction pote
Externí odkaz:
https://doaj.org/article/7b0e025eda0340a0a107ab964e2f6c59
Autor:
Huawei Weng, Prem Raj Shrestha, Huangming Hong, Zegeng Chen, Le Yu, Yuyi Yao, Zhihui Zhang, Liqun Zou, Bo Zhu, Hui Zhou, Xianling Liu, Yao Liu, Hongqiang Guo, He Huang, Tongyu Lin
Publikováno v:
Cancer Medicine, Vol 12, Iss 23, Pp 21188-21198 (2023)
Abstract Background Primary breast diffuse large B‐cell lymphoma (PB‐DLBCL) is a rare subtype of extranodal DLBCL, and the standard treatment remains controversial. In this study, we aimed to define the optimal treatment management in the rituxim
Externí odkaz:
https://doaj.org/article/724f7ed793c64f36939b2b4721cab06b
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
High-grade gliomas (HGG) pose significant challenges in modern tumour therapy due to the distinct biological properties and limitations of the blood-brain barrier. This review discusses recent advancements in HGG treatment, particularly in the contex
Externí odkaz:
https://doaj.org/article/bef21aef3ff94848ac1a126474e1e695
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background The relationship between migraine and breast cancer risk has generated conflicting findings. We attempted to assess the association between migraine and breast cancer risk using Mendelian randomization (MR) analysis. Methods We se
Externí odkaz:
https://doaj.org/article/89b96c1c3e014a90bb95fed0cb356cd7
Autor:
Yuqin Song, Junning Cao, Qingyuan Zhang, Caixia Li, Lugui Qiu, Junyuan Qi, Huilai Zhang, Wenyu Li, Lihong Liu, Hongmei Jing, Keshu Zhou, Weijing Zhang, Liling Zhang, Daqi Li, Liqun Zou, Haiyan Yang, Wenbin Qian, Hui Zhou, Jianda Hu, Hongyan Yin, Sisi Fu, Songhua Fan, Qian Xu, Jian Wang, Xiaoyun Jia, Guangxiu Dai, Weiguo Su, Jun Zhu
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Sovleplenib (HMPL-523) is a selective spleen tyrosine kinase (Syk) inhibitor with antitumor activity in preclinical models of B-cell malignancy. We conducted a dose-escalation and dose-expansion phase I study of sovleplenib in patients with relapsed/
Externí odkaz:
https://doaj.org/article/2a631b479f3e41d4be020eef1b73030c
Autor:
Lu Ye, Fei Zhou, Dongdong Cheng, Ming Xie, Xiaoli Yan, Yuyu Xue, Qian Yang, Rong Jia, Lili Zhong, Li Yang, Liqun Zou, Na Huang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectivesThe current study aims to evaluate the safety and efficacy of anti-CD38 monoclonal antibodies (mAbs) among patients with relapsed/refractory multiple myeloma (RRMM) through meta-analysis.MethodsAs of June 2023, we searched PubMed, Web of Sc
Externí odkaz:
https://doaj.org/article/fe3f2dda1e8f4ecaa1e2ea634cf39eb6
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 9458-9470 (2023)
Abstract Background Nasal‐type extranodal natural killer (NK)/T cell lymphoma (ENKTL) is a rare and aggressive type of lymphoma. The optimal chemotherapy regimen for ENKTL has not yet been established. In this study, we compared the LVDP (L‐aspar
Externí odkaz:
https://doaj.org/article/13c2fb20653e4e6d9f6fa00d2dcc5a9e